Skip to main content

Effectiveness of non-pharmacological interventions on metabolic control in adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

In brief

Lifestyle programs lower HbA1c by about 0.4% in type 2 diabetes

A meta-analysis of 42 randomized trials (9,586 adults) found non-pharmacologic interventions reduced HbA1c by 0.43 percentage points, fasting glucose by 0.6 mmol/L, waist circumference by 2.3 cm, and systolic blood pressure by 1.7 mmHg, without affecting triglycerides or HDL. Benefits were modest and varied across studies, so clinicians should weigh the heterogeneity before routine adoption.

Journal
Diabetes research and clinical practice (Q1)
Published
11 September 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Tran Thi My, Nantiya Watthayu
PMID
42727859
DOI
10.1016/j.diabres.2026.113556

Why clinicians should know about it

  • Picked for Internal Medicine (top studies of the week, 13 September 2026): Meta-analysis of RCTs improving metabolic control in T2DM
  • Picked for Family Practice (top studies of the week, 13 September 2026): Meta‑analysis of non‑pharmacological T2DM interventions

Abstract

This systematic review and meta-analysis evaluated the effectiveness of non-pharmacological interventions in improving MetS-related metabolic-control outcomes among adults with type 2 diabetes mellitus. PubMed, Scopus, ScienceDirect, and the Cochrane Library were searched from January 2005 to June 2025. Eligible randomised controlled trials compared non-pharmacological interventions with usual care, standard care, or no intervention and reported at least three prespecified metabolic syndrome components. Non-randomised studies and pharmacological, surgical, medical-device, supplement-based, or insufficiently reported interventions were excluded. Random-effects models used restricted maximum-likelihood estimation with the Knapp-Hartung adjustment, and risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Forty-two trials involving 9,586 participants were included. Interventions significantly reduced glycated haemoglobin (HbA1c; mean difference [MD] -0.43 percentage points, 95% confidence interval [CI] -0.55 to -0.32), fasting glucose (MD -0.57 mmol/L, 95% CI -0.83 to -0.32), waist circumference (MD -2.25 cm, 95% CI -3.32 to -1.19), systolic blood pressure (MD -1.66 mmHg, 95% CI -2.98 to -0.34), and diastolic blood pressure (MD -0.93 mmHg, 95% CI -1.56 to -0.30), but not triglycerides or high-density lipoprotein cholesterol. Continuous meta-regression showed no significant duration effect. Non-pharmacological interventions provide modest cardiometabolic benefits, although heterogeneity and possible small-study effects warrant caution. Registration: PROSPERO CRD420251073643.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.